Syndax Pharmaceuticals (SNDX) EBIT Margin (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly EBIT Margin of 52.73% for Q1 2026, up 36518.0% year-over-year from N/an in Q1 2025, and up 42.06% quarter-over-quarter from 91.01% in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) EBIT Margin (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' EBIT Margin history runs 10 years deep, the most recent figure standing at 52.73% for Q1 2026.
- In Q1 2026, EBIT Margin rose 36518.0% year-over-year to 52.73%; the TTM figure through Mar 2026 stood at 102.81% (up 68379.0% YoY), while the FY2025 annual figure was 158.45%, up 127598.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 52.73%, up from 91.01% in the prior quarter.
- The five-year high for EBIT Margin was 52.73% in Q1 2026, with the low at 2120.46% in Q2 2024.
- The 3-year median for EBIT Margin is 300.31% (2025), against an average of 620.17%.
- The sharpest annual moves came in 2025 and 2026: EBIT Margin surged 193775 bps in 2025, then soared 36518 bps in 2026.
- Syndax Pharmaceuticals' EBIT Margin stood at 1254.75% in 2024, then soared by 93 bps to 91.01% in 2025, then surged by 42 bps to 52.73% in 2026.
- Business Quant data shows SNDX's EBIT Margin at 52.73% in Q1 2026, 91.01% in Q4 2025, and 125.19% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn | -54.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -54.95% |
| Mar 31, 2026 | -52.73% |
| Dec 31, 2025 | -91.01% |
| Sep 30, 2025 | -125.19% |
| Jun 30, 2025 | -182.71% |
| Mar 31, 2025 | -417.91% |
| Dec 31, 2024 | -1,254.75% |
| Sep 30, 2024 | -716.62% |
| Jun 30, 2024 | -2,120.46% |
| Dec 31, 2021 | 75.65% |
| Sep 30, 2021 | -161.87% |
| Jun 30, 2021 | -5,892.88% |
| Mar 31, 2021 | -7,167.02% |
| Dec 31, 2020 | -5,226.32% |
| Sep 30, 2020 | -5,238.26% |
| Jun 30, 2020 | -4,382.59% |
| Mar 31, 2020 | -3,984.17% |
| Dec 31, 2019 | -3,738.16% |
| Sep 30, 2019 | -3,469.39% |
| Jun 30, 2019 | -4,056.46% |